| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| 迈富时管理 | 420,000 | 1.15% | 0.09% | 9 months |
| Ginkgo Fund | 840,200 | 2.30% | 0.18% | 9 months |
| 骏升 | 2,100,800 | 5.75% | 0.50% | 9 months |
| 黎慧凤 | 420,000 | 1.15% | 0.09% | 9 months |
| 邓海峰 | 420,000 | 1.15% | 0.09% | 9 months |
| Rank | % of international placing | % of global offering |
|---|---|---|
| 前1名 | — | — |
The IPO attracted overwhelming demand with an oversubscription ratio of 5,341.66 times, signaling extreme market enthusiasm. Despite 256,072 valid applications, only 18,279 were successful, yielding a hit rate of just 7.14%. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
A-tail (甲尾) applicants with HKD 200,000 could expect just 0.2162 lots, while B-head (乙头) applicants with HKD 300,000 received only 0.3001 lots, a disproportionate 39% increase in allocation for 50% more capital. This narrow gap makes the B-head tier economically inefficient, especially after broker fees. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Mainland Chinese investors accounted for 62.6% of participants, highlighting strong cross-border appetite for this biotech listing. The applicant base was predominantly male (61.4%) with an average age of 43, typical for high-risk speculative IPOs. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
This page shows allotment analysis for Innogen-B (02591): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

